Valproate-risperidone versus valproate-lithium combination in acute mania

We evaluated the efficacy of valproate plus risperidone versus valproate plus lithium combination in the treatment of acute mania. In 2-week, randomized, double-blind, parallel group study, 46 acute manic patients according to DSM-IV criteria were randomly assigned to receive combination of valproate 20 mg/ kg/day plus risperidone 2-4 mg/day [n=23] or lithium600-1200 mg/day [n=23]. The assessment of efficacy measures were according to Young Mania Rating Scale [YMRS] and Clinical Global Impressions-Severity [CGI-S] and Improvement [CGI-I] scale. Other effectiveness measures included YMRS response [YMRS reduction >50%] and YMRS remission [YMRS total scores

Association of alopecia universalis, generalized vitiligo, and Graves'diseases

We present a 21-years old woman with alopecia universalis, generalized vitiligo, and Graves' disease. She had had thyroidectomy in early childhood and was receiving replacement therapy with levothyroxine. The patient was treated with systemic PUVA and glucocorticoid in combination with topical treatment for alopecia. After 6 months of treatment, alopecia was reversed but vitiligo was unchanged